2018
DOI: 10.1038/s41598-018-26459-5
|View full text |Cite
|
Sign up to set email alerts
|

Enhanced ZnR/GPR39 Activity in Breast Cancer, an Alternative Trigger of Signaling Leading to Cell Growth

Abstract: Acquired resistance to the estrogen receptor (ER) antagonist tamoxifen, is a major obstacle in treatment of breast cancer. Changes in Zn2+ accumulation and distribution are associated with tamoxifen-resistance and breast cancer progression. The Zn2+-sensing G-protein coupled receptor, ZnR/GPR39, triggers signaling leading to cell growth, but a role for this receptor in breast cancer in unknown. Using fluorescence imaging, we found Zn2+-dependent Ca2+ release, mediated by ZnR/GPR39 activity, in TAMR tamoxifen-r… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
20
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
7

Relationship

2
5

Authors

Journals

citations
Cited by 19 publications
(22 citation statements)
references
References 76 publications
(86 reference statements)
2
20
0
Order By: Relevance
“…Activation of ZnR/GPR39, by Zn 2+ , triggered upregulation of MAPK and AKT/PI3K signaling pathways in ZnR/GPR39 expressing breast cancer cells. In agreement, unbiased screens identified a correlation between upregulation of GPR39 and the aggressiveness of breast cancer cell lines and tissues [7,8]. Changes in Zn 2+ levels and in the expression of Zn 2+ transporters are also monitored in breast cancer tissues [9][10][11][12], this dys-homeostasis may trigger release of Zn 2+ and subsequent activation of ZnR/GPR39.…”
Section: Introductionsupporting
confidence: 53%
See 2 more Smart Citations
“…Activation of ZnR/GPR39, by Zn 2+ , triggered upregulation of MAPK and AKT/PI3K signaling pathways in ZnR/GPR39 expressing breast cancer cells. In agreement, unbiased screens identified a correlation between upregulation of GPR39 and the aggressiveness of breast cancer cell lines and tissues [7,8]. Changes in Zn 2+ levels and in the expression of Zn 2+ transporters are also monitored in breast cancer tissues [9][10][11][12], this dys-homeostasis may trigger release of Zn 2+ and subsequent activation of ZnR/GPR39.…”
Section: Introductionsupporting
confidence: 53%
“…1A). The response was triggered by a brief exposure to 200µM Zn 2+ , which activates ZnR/GPR39 in breast cancers cells but does not induce intracellular Zn 2+ rise [7].…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Secondary anti-mouse and anti-rabbit antibodies (Jackson Immunoesearch, West Grove, PA, USA) were used at dilutions of 1:20,000 and 1:40,000, respectively. Densitometry analysis of expression level was performed using EZQuant-Gel software (EZQuant, Hertzliya Pituach, Israel) as previously described [55].…”
Section: Immunoblot Analysismentioning
confidence: 99%
“…NCOA1 was found to promote angiogenesis in breast cancers [33]. SLC39A7 is a potential oncogene in colorectal cancer [34]. IDH3B is upregulated in breast cancer and is significantly involved in energy metabolism in tumor progression [35,36].…”
Section: Quantitative and Qualitative Assessment Of Quadmutnetex Resultsmentioning
confidence: 99%